Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ina Landel

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
ACS Medicinal Chemistry Letters|March 19, 2020
Spotlight on AKT: Current Therapeutic ChallengesIna Landel, Lena Quambusch, Laura Depta, et al.
Chemmedchem|August 7, 2018
RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer TherapeuticsPatrik Wolle, Jörn Weisner, Marina Keul, et al.
Angewandte Chemie (International Ed. in English)|October 5, 2019
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-SelectivityLena Quambusch, Ina Landel, Laura Depta, et al.
Chemmedchem|February 16, 2022
Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment ApproachLeandi van der Westhuizen, Jörn Weisner, Abu Taher, et al.
Chemical Science|April 19, 2019
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase AktNiklas Uhlenbrock, Steven Smith, Jörn Weisner, et al.
Nature Communications|September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsLena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
Cancer Research|March 13, 2019
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal CancerJörn Weisner, Ina Landel, Christoph Reintjes, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|March 19, 2020
Spotlight on AKT: Current Therapeutic ChallengesIna Landel, Lena Quambusch, Laura Depta, et al.
Chemmedchem|August 7, 2018
RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer TherapeuticsPatrik Wolle, Jörn Weisner, Marina Keul, et al.
Angewandte Chemie (International Ed. in English)|October 5, 2019
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-SelectivityLena Quambusch, Ina Landel, Laura Depta, et al.
Chemmedchem|February 16, 2022
Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment ApproachLeandi van der Westhuizen, Jörn Weisner, Abu Taher, et al.
Chemical Science|April 19, 2019
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase AktNiklas Uhlenbrock, Steven Smith, Jörn Weisner, et al.
Nature Communications|September 7, 2021
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsLena Quambusch, Laura Depta, Ina Landel, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
Cancer Research|March 13, 2019
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal CancerJörn Weisner, Ina Landel, Christoph Reintjes, et al.
Pageof 1